Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Desbois D, et al. Antimicrob Agents Chemother. 2008 Apr;52(4):1545-8. doi: 10.1128/AAC.01284-07. Epub 2008 Jan 28. Antimicrob Agents Chemother. 2008. PMID: 18227188 Free PMC article.
Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.
Plantier JC, Vergne L, Damond F, MBoup S, MPoudi-NGole E, Buzelay L, Farfara I, Brand D, Peeters M, Brun-Vézinet F, Delaporte E, Barin F. Plantier JC, et al. J Clin Microbiol. 2002 Mar;40(3):1010-22. doi: 10.1128/JCM.40.3.1010-1022.2002. J Clin Microbiol. 2002. PMID: 11880431 Free PMC article.
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group. Joly V, et al. Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13. doi: 10.1128/AAC.46.6.1906-1913.2002. Antimicrob Agents Chemother. 2002. PMID: 12019107 Free PMC article. Clinical Trial.
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group. Descamps D, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. doi: 10.1097/00126334-200212150-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12473833 Clinical Trial.
358 results